유럽 연합 - 영어 - EMA (European Medicines Agency)

roche registration gmbh - cobimetinib hemifumarate - melanoma - antineoplastic agents - cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.

유럽 연합 - 영어 - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - breast neoplasms - antineoplastic agents - ibrance is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

유럽 연합 - 영어 - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilate - carcinoma, renal cell - antineoplastic agents - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

유럽 연합 - 영어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - carcinoma, non-small-cell lung - antineoplastic agents - vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after first line chemotherapy.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, non-small-cell lung - antineoplastic agents - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor.alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

eusa pharma ltd - tivozanib hydrochloride monohydrate - capsule - .89mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - binimetinib - tablet - 15mg

이스라엘 - 영어 - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - capsules - palbociclib 100 mg - palbociclib - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with:- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or- fulvestrant in patients with disease progression following endocrine therapy

이스라엘 - 영어 - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - capsules - palbociclib 125 mg - palbociclib - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with:- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or- fulvestrant in patients with disease progression following endocrine therapy

이스라엘 - 영어 - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - capsules - palbociclib 75 mg - palbociclib - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with:- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or- fulvestrant in patients with disease progression following endocrine therapy